Treatment patterns and deep molecular response in chronic phase–chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study

Jorge Cortes, Lynn Huynh, Estella Mendelson, Patricia Brandt, Darshan Dalal, Maral DerSarkissian, Diego Cortina, Sahil Narkhede, Mei Sheng Duh

Research output: Contribution to journalArticle

Abstract

Achievement of MR4.5 (BCR-ABL1 ≤ 0.0032% on international scale) is an important goal of tyrosine kinase inhibitor (TKI) treatment for patients with chronic myeloid leukemia (CML). This study describes treatment patterns by region and assesses time to achieve MR4.5 in patients with CML–chronic phase (CP) treated with second-line nilotinib or dasatinib in 10 countries. A multivariate Cox proportional hazards model was used to assess time to MR4.5 for nilotinib versus dasatinib. The model accounted for the competing-risk event of TKI resistance, included random effects for country clustering, and was adjusted for baseline covariates. The study included 280 patients treated with either nilotinib (N = 135 [48%]) or dasatinib (N = 145 [52%]) as second-line TKI with median treatment durations of 19.1 and 18.7 months, respectively. Nilotinib was observed to be better in achieving MR4.5 than dasatinib (adjusted hazard ratio = 1.37, 95% CI [1.11, 1.69]) suggesting second-line nilotinib may perform better in achieving MR4.5 than dasatinib.

Original languageEnglish (US)
Pages (from-to)98-107
Number of pages10
JournalLeukemia and Lymphoma
Volume61
Issue number1
DOIs
StatePublished - Jan 2 2020
Externally publishedYes

Keywords

  • Chronic myeloid leukemia
  • deep molecular response
  • nilotinib
  • targeted therapies
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Treatment patterns and deep molecular response in chronic phase–chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study'. Together they form a unique fingerprint.

  • Cite this